Spreadsheet: 07187956-8055-4366-88eb-2d466d7b4eca
Sheet: tab17

 | Estimated Vaccination Coverage*,† among Adolescents Aged 13-17 Years§, by Race/ethnicity¶  for Selected Vaccines  -- National Immunization Survey-Teen, United States, 2013
Vaccines | White only, non-Hispanic | Black only, non-Hispanic | Hispanic | American Indian/Alaska Native only, non-Hispanic | Asian,                           non-Hispanic
 | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.)
≥2 doses of MMR** | 92.8(±0.8) | 91.1(±2.4) | 90.2(±2.3) | 93.5(±5.2) | 90.8(±6.0)
[NAME] 3 doses of HepB†† | 93.8(±0.8) | 93.2(±2.1) | 92.8(±2.0) | 93.4(±5.3) | 87.8(±6.6)
Varicella
History of varicella disease§§ | 26.8(±1.4) | 22.6(±3.5) | 24.6(±3.0) | 36.6(±10.6) | 24.2(±6.7)
Among adolescents without history of disease:
≥1 dose | 95.3(±0.8) | 94.3(±2.6) | 94.5(±2.5) | 95.7(±3.7) | 94.3(±6.7)
≥2 dose | 77.7(±1.5) | 77.9(±3.6) | 80.3(±3.5) | 78.7(±9.8) | 85.2(±8.1)
History of disease or received ≥2 doses varicella vaccination | 83.7(±1.1) | 82.9(±3.0) | 85.2(±2.7) | 86.5(±6.4) | 88.8(±6.3)
Td or Tdap¶¶
≥1 dose Td or [NAME] | 88.8(±1.0) | 87.4(±2.8) | 90.5(±2.2) | 87.2(±7.0) | 92.5(±3.1)
≥1 dose [NAME] | 85.9(±1.1) | 84.1(±3.0) | 87.1(±2.4) | 85.3(±7.2) | 89.7(±3.6)
≥1 dose of MenACWY*** | 75.6(±1.3) | 77.0(±3.3) | 83.4(±2.8) | 71.7(±11.1) | 83.8(±7.1)
HPV†††
FEMALE
≥1 dose | 53.1(±2.3) | 55.8(±5.2) | 67.5(±5.0) | 73.3(±14.7) | 57.0(±11.4)
≥2 doses | 44.0(±2.2) | 45.6(±5.2) | 57.7(±5.4) | 57.3(±15.2) | 47.2(±11.2)
≥3 doses | 34.9(±2.1) | 34.2(±4.8) | 44.8(±5.6) | 43.2(±14.2) | 40.4(±11.0)
MALE
≥1 dose | 26.7(±1.9) | 42.2(±5.5) | 49.6(±5.2) | 38.6(±14.0) | 26.3(±8.9)
≥2 doses | 18.5(±1.7) | 27.5(±4.8) | 34.5(±5.3) | 24.8(±11.4) | 19.5(±8.0)
≥3 doses | 11.1(±1.3) | 15.7(±3.8) | 20.3(±4.5) | NA | 9.1(±4.5)
3 dose series completion§§§
Females | 71.8(±2.9) | 63.7(±7.3) | 69.5(±6.1) | 60.1(±16.9) | 77.2(±12.1)
Males | 51.1(±4.7) | 44.8(±8.8) | 47.4(±9.0) | 48.4(±20.0) | 40.0(±18.8)
 | *  Estimate presented as point estimate (%) ± 95% confidence interval (CI). Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588.
 | † Estimates with confidence intervals >20 may not be reliable.
 | § Adolescents in the 2013 NIS-Teen were born January 1995 through February 2001. Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. National estimates do not include adolescents living in Guam (n=363) and the U.S. Virgin Islands (n=332).
 | ¶  Reported by parent/guardian respondent.  Adolescents of Hispanic ethnicity may be of any race. Native Hawaiian or other Pacific Islanders and persons of multiple races were not included because of small sample sizes.
 | **  [NAME] 2 doses of measles-mumps-rubella (MMR) vaccine.
 | †† ≥3 doses of hepatitis B (Hep B) vaccine.
 | §§By parent/guardian report or provider records.
 | ¶¶  [NAME] 1 dose of tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis ([NAME]), since age 10 years.
 | *** ≥1 dose of meningococcal conjugate vaccine or meningococcal -unknown type (MenACWY) vaccine.
 | ††† ≥1dose of human papillomavirus (HPV) vaccine, either quadrivalent or bivalent. Percentages reported among females (n=8,710) and males (n=9,554). Some adolescents may have received more than the three recommended HPV doses.
 | §§§ Percent of males or females who received three doses among those who had at least one human papillomavirus (HPV) vaccine dose with at least 24 weeks between the first dose and the interview date.